Abstract: The present disclosure relates to antibodies that specifically bind and neutralize interleukin-1? (IL-1?), and to the use of such antibodies for the therapeutic treatment of IL-1?-mediated diseases and disorders.

Abstract: The present disclosure is related to antibodies (e.g., human antibodies) and antigen-binding fragments thereof that specifically bind and neutralize (human) thymic stromal lymphopoietin (TSLP). Such molecules may have modified Fc regions that increase antibody half-life, increase resistance to proteases, and/or reduce ability to interact with Fc gamma receptors. These molecules are useful for treatment of allergic and non-allergic inflammation associated with TSLP-related disorders and diseases.

Abstract: The present disclosure relates to designs and applications of Variable Heavy Only (VHO) domain regions. The present disclosure provides a VHO library of polynucleotides encoding VHO domains, wherein the VHO domains are designed based on the Vh domain of a human Vh family, and a method of generating the VHO library. The present disclosure also provides a phage library displaying the VHO domains encoded by the VHO library through the use of M13 bacteriophage minor coat proteins such as pIX and pVII and a method of generating the phage library. The present disclosure also provides a method of screening the phage library to identify VHO candidates that are capable of binding a target of interest.

Abstract: The present disclosure relates to the application of a shielded and homing bispecific antibody as an effective and tissue specific treatment of cancers such as breast, lung, gastric cancers, and other HER2 over-expressed cancers. The homing domain increases the local concentration of the bispecific antibody in the tumor microenvironment, and the shielding employs masking domains that are fused via protease-cleavable linkers to the Fab domains targeting a human epidermal growth factor receptor 2 family protein and Fab domains targeting an angiogenic vascular endothelial growth factor pathway associated target. The unmasking of the shielded bispecific antibody occurs predominantly by proteases and enzymes in the tumor microenvironment. The application of such bispecific antibody minimizes systemic toxicity and expands the therapeutic index.

Abstract: The present disclosure relates to a shielded biologic with a masking domain, e.g., based on Insulin-like Growth Factor 2 (IGF2), fused to the Fab domain of an antibody via protease-cleavable linker to mask the antigen binding capability of the antibody, and to the use of said shielded biologic for effective and site-specific disease treatment while reducing systematic toxicity.

Abstract: The present disclosure relates to bi-specific antibodies that specifically bind and neutralize both tumor necrosis factor ? (TNF?) and interleukin-1? (IL-1?), and to the use of such bispecific antibodies for the therapeutic treatment of TNF? and IL-1?-mediated diseases and disorders.